Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women

Journal of Bone and Mineral Research

Volumn 21, Issue 7, 2006, Pages 1106-1112

  Zoehrer, Ruth ^a   Roschger, Paul ^a,d   Paschalis, Eleftherios P ^a   Hofstaetter, Jochen G ^a   Durchschlag, Erich ^a   Fratzl, Peter ^b   Phipps, Roger ^c   Klaushofer, Klaus ^a  

^a HANUSCH HOSPITAL   (Austria)

^b MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES   (Germany)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Bone mineralization density distribution; Long term risedronate treatment; Postmenopausal osteoporosis; Quantitative backscattered electron imaging; Triple biopsies

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MATRIX; BONE MINERALIZATION; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; ILIAC CREST; LONG TERM CARE; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; VITAMIN SUPPLEMENTATION;

BIOPSY; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIFICATION, PHYSIOLOGIC; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; TIME FACTORS;

EID: 33745485305     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060401     Document Type: Article

References (28)

1. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
2. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352.
3. Watts N BR, Smith C, Li Z, Eastell R, Pack S, Lindsay R 2000 BMD changes explains only a fraction of the observed fracture risk reduction in risedronate-treated patients. Osteoporos Int 11(Suppl 2):S203.
4. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261.
5. Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD 2005 How useful are measurements of BMD and bone turnover? Curr Med Res Opin 21:545-554.
6. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
7. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Qin G, Christiansen C 2005 The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: Results from the Prospective Epidemiological Risk Factors study. Osteoporos Int 28:1-7.
8. Watts NB, Geusens P, Barton IP, Felsenberg D 2005 Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 20:2097-2104.
9. Delmas PD, Zhengqing L, Cooper C 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs. Some issues with meta-analyses. J Bone Miner Res 19:330-357.
10. Fratzl P, Gupta HS, Paschalis EP, Roschger P 2004 Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem 14:2115-2123.
11. Roschger P, Fratzl P, Eschberger J, Klaushofer K 1998 Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 23:319-326.
12. Roschger P, Gupta HS, Berzlanovich A, Ittner G, Dempster DW, Fratzl P, Cosman F, Parisien M, Lindsay R, Nieves JW, Klaushofer K 2003 Constant mineralization density distribution in cancellous human bone. Bone 32:316-323.
13. Roschger P, Plenk H Jr, Klaushofer K, Eschberger J 1995 A new scanning electron microscopy approach to the quantification of bone mineral distribution: Backscattered electron image grey-levels correlated to calcium K alpha-line intensities. Scanning Microsc 9:75-86.
14. Fink-Eriksen E, Axelrod DW, Melsen F 1994 Bone Histomorphometry. Raven Press, New York, NY, USA.
15. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster D, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment. J Clin Endocrinol Metab 88:150-156.
16. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191.
17. Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, Boskey AL, Klaushofer K, Fratzl P, Camacho NP 2005 Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 36:150-158.
18. Roschger P, Fratzl P, Klaushofer K, Rodan G 1997 Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs. Bone 20:393-397.
19. Currey JD 1984 Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci 304:509-518.
20. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694.
21. Ste-Marie LG, Sod E, Johnson T, Chines A 2004 Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75:469-476.
22. Eriksen EF, Melsen F, Sod E, Barton I, Chines A 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620-625.
23. Loveridge N, Power J, Reeve J, Boyde A 2004 Bone mineralization density and femoral neck fragility. Bone 35:929-941.
24. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller PD, Broy SB, Kagan R, Chen ERAP, Thompson DE, dePapp AE 2005 Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20:141-151.
25. Borah B, Ritman EL, Dufresne TE, Jorgensen SM, Liu S, Sacha J, Phipps J, Turner RT 2005 The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: Correlation to histomorphometric indices of turnover. Bone 37:1-9.
26. Gupta HS, Wagermaier W, Zickler GA, Aroush DRB, Funari SS, Roschger P, Wagner HD, Fratzl P 2005 Nanoscale deformation mechanisms in bone. Nano Lett 5:2108-2111.
27. Peterlik H, Roschger P, Klaushofer K, Fratzl P 2006 From brittle to ductile fracture of bone. Nat Mater 5:52-55.
28. Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wendoroth D, Cooper C, Reginster J-Y 2003 Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone 32:120-126.